Karius
Karius Taps Capstone Health Alliance to Broaden Patient Access to Infectious Disease Testing
Doctors at Capstone member hospitals will be able to more easily order the Karius Test for patients harboring hard-to-diagnose infections.
Karius Receives NY State Approval for Infectious Disease Liquid Biopsy Test
The permit covers the test for all five pathogen categories: bacteriology, mycobacteriology, mycology, parasitology, and virology.
The liquid biopsy test compares fragments of cfDNA to a reference database of more than 1,400 microbial pathogens to determine infection.
The firm argues that its tests allows hospitals to expedite patient treatment, while curbing the costs of one-off tests and medication, and minimizing the length of a patient's stay.
Karius Raises $165M in Series B Financing Round
The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease.